病毒载体在 RNAi 抗病毒治疗中是否有效？
Are Viral Vectors Any Good for RNAi Antiviral Therapy?
机构信息
PanTherapeutics, Route de Lavaux 49, CH1095 Lutry, Switzerland.
出版信息
Viruses. 2020 Oct 20;12(10):1189. doi: 10.3390/v12101189.
RNA interference (RNAi) represents a novel approach for alternative antiviral therapy. However, issues related to RNA delivery and stability have presented serious obstacles for obtaining good therapeutic efficacy. Viral vectors are capable of efficient delivery of RNAi as short interfering RNA (siRNA), short hairpin RNA (shRNA) and micro-RNA (miRNA). Efficacy in gene silencing for therapeutic applications against viral diseases has been demonstrated in various animal models. Rotavirus (RV) miR-7 can inhibit rotavirus replication by targeting the RV nonstructural protein 5. Viral gene silencing by targeting the RNAi pathway showed efficient suppression of hepatitis B virus replication by adeno-associated virus (AAV)-based delivery of RNAi hepatitis B virus (HBV) cassettes. Hepatitis C virus replication has been targeted by short hairpin RNA molecules expressed from lentivirus vectors. Potentially, RNAi-based approaches could be suitable for antiviral drugs against COVID-19.
RNA 干扰 (RNAi) 代表了一种新的抗病毒治疗方法。然而，与 RNA 递送和稳定性相关的问题为获得良好的治疗效果带来了严重的障碍。病毒载体能够有效地递送 RNAi，如短干扰 RNA（siRNA）、短发夹 RNA（shRNA）和 micro-RNA（miRNA）。在各种动物模型中，针对病毒疾病的基因沉默治疗应用已证明其疗效。轮状病毒 (RV) miR-7 可以通过靶向 RV 非结构蛋白 5 来抑制轮状病毒复制。通过靶向 RNAi 通路的病毒基因沉默显示，通过腺相关病毒 (AAV) 递送 RNAi 乙型肝炎病毒 (HBV) 盒，能够有效抑制乙型肝炎病毒的复制。丙型肝炎病毒的复制已被来自慢病毒载体表达的短发夹 RNA 分子靶向。潜在地，基于 RNAi 的方法可能适用于针对 COVID-19 的抗病毒药物。
Zotero 插件